RU2005138369A - Фармацевтически полезные соли производных карбоновой кислоты - Google Patents
Фармацевтически полезные соли производных карбоновой кислоты Download PDFInfo
- Publication number
- RU2005138369A RU2005138369A RU2005138369/04A RU2005138369A RU2005138369A RU 2005138369 A RU2005138369 A RU 2005138369A RU 2005138369/04 A RU2005138369/04 A RU 2005138369/04A RU 2005138369 A RU2005138369 A RU 2005138369A RU 2005138369 A RU2005138369 A RU 2005138369A
- Authority
- RU
- Russia
- Prior art keywords
- salt
- compound according
- dyslipidemia
- treating
- pharmaceutally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (11)
1. Кальциевая или магниевая соль (2S)-2-этокси-3-(4-{2-[гексил(2-фенилэтил)-амино]-2-оксоэтокси}фенил)пропановой кислоты.
2. Кальциевая соль (2S)-2-этокси-3-(4-{2-[гексил(2-фенилэтил)амино]-2-оксоэтокси}фенил)пропановой кислоты.
3. Соль по п.1 или 2, которая может быть сольватом, гидратом, смешанным сольватом/гидратом, ансольватом или ангидратом.
4. Соль по п.1 или 2 в кристаллической или частично кристаллической форме.
5. Соль по п.1 или 2 в форме смешанной соли вместе с фармацевтически неактивным противоионом.
6. Соль по п.2, где фармацевтически неактивным противоионом является [CaCl]+.
7. Фармацевтический препарат, содержащий соединение по любому из пп.1-6 в смеси с фармацевтически приемлемыми адъювантами, разбавителями и/или носителями.
8. Способ лечения или предупреждения липидных расстройств (дислипидемии) как ассоциированных, так и не ассоциированных с резистентностью к инсулину, включающий введение соединения по любому из пп.1-6 млекопитающему, которое в этом нуждается.
9. Применение соединения по любому из пп.1-6 в изготовлении лекарства для лечения липидных расстройств (дислипидемии), как ассоциированных, так и не ассоциированных с резистентностью к инсулину.
10. Способ лечения или предупреждения диабета типа 2, включающий введение эффективного количества соединения формулы I по любому из пп.1-6 млекопитающему, которое в этом нуждается.
11. Фармацевтическая композиция, содержащая соединение по любому из пп.1-6, в сочетании с другим терапевтическим агентом, который является полезным в лечении расстройств, ассоциированных с развитием и прогрессированием атеросклероза, таких как гипертензия, гиперлипидемии, дислипидемии, диабет и ожирение.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0314136.3 | 2003-06-18 | ||
| GBGB0314136.3A GB0314136D0 (en) | 2003-06-18 | 2003-06-18 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005138369A true RU2005138369A (ru) | 2007-07-27 |
Family
ID=27636795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005138369/04A RU2005138369A (ru) | 2003-06-18 | 2004-06-16 | Фармацевтически полезные соли производных карбоновой кислоты |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20060194879A1 (ru) |
| EP (1) | EP1638921A1 (ru) |
| JP (1) | JP3836498B1 (ru) |
| KR (1) | KR20060017646A (ru) |
| CN (1) | CN1805922A (ru) |
| AR (1) | AR044802A1 (ru) |
| AU (1) | AU2004247611A1 (ru) |
| BR (1) | BRPI0411455A (ru) |
| CA (1) | CA2527608A1 (ru) |
| CO (1) | CO5650229A2 (ru) |
| GB (1) | GB0314136D0 (ru) |
| IL (1) | IL172168A0 (ru) |
| IS (1) | IS8232A (ru) |
| MX (1) | MXPA05013713A (ru) |
| NO (1) | NO20055923L (ru) |
| RU (1) | RU2005138369A (ru) |
| SA (1) | SA04250170B1 (ru) |
| TW (1) | TW200503678A (ru) |
| UY (1) | UY28371A1 (ru) |
| WO (1) | WO2004110985A1 (ru) |
| ZA (1) | ZA200510199B (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0229931D0 (en) * | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| EP1517883B8 (en) | 2002-06-20 | 2008-05-21 | AstraZeneca AB | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| WO2007004957A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | Novel crystalline form |
| AR055073A1 (es) * | 2005-07-11 | 2007-08-01 | Astrazeneca Ab | Agentes terapeuticos |
| FR2903985B1 (fr) | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2904316B1 (fr) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
| UY30648A1 (es) * | 2006-10-20 | 2008-05-02 | Janssen Pharmaceutica Nv | Formas salinas de compuestos de benzotienilo sustituido |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL145732A0 (en) * | 1999-04-06 | 2002-07-25 | Sankyo Co | α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
-
2003
- 2003-06-18 GB GBGB0314136.3A patent/GB0314136D0/en not_active Ceased
-
2004
- 2004-06-09 TW TW093116599A patent/TW200503678A/zh unknown
- 2004-06-16 RU RU2005138369/04A patent/RU2005138369A/ru not_active Application Discontinuation
- 2004-06-16 SA SA04250170A patent/SA04250170B1/ar unknown
- 2004-06-16 US US10/560,127 patent/US20060194879A1/en not_active Abandoned
- 2004-06-16 MX MXPA05013713A patent/MXPA05013713A/es not_active Application Discontinuation
- 2004-06-16 BR BRPI0411455-8A patent/BRPI0411455A/pt not_active IP Right Cessation
- 2004-06-16 CA CA002527608A patent/CA2527608A1/en not_active Abandoned
- 2004-06-16 EP EP04736956A patent/EP1638921A1/en not_active Withdrawn
- 2004-06-16 CN CNA2004800168384A patent/CN1805922A/zh active Pending
- 2004-06-16 AU AU2004247611A patent/AU2004247611A1/en not_active Abandoned
- 2004-06-16 WO PCT/SE2004/000965 patent/WO2004110985A1/en active Application Filing
- 2004-06-16 JP JP2006517040A patent/JP3836498B1/ja not_active Expired - Fee Related
- 2004-06-16 KR KR1020057024066A patent/KR20060017646A/ko not_active Application Discontinuation
- 2004-06-17 AR ARP040102112A patent/AR044802A1/es not_active Application Discontinuation
- 2004-06-17 UY UY28371A patent/UY28371A1/es not_active Application Discontinuation
-
2005
- 2005-11-24 IL IL172168A patent/IL172168A0/en unknown
- 2005-12-13 NO NO20055923A patent/NO20055923L/no not_active Application Discontinuation
- 2005-12-14 ZA ZA200510199A patent/ZA200510199B/en unknown
- 2005-12-28 CO CO05130776A patent/CO5650229A2/es unknown
-
2006
- 2006-01-13 IS IS8232A patent/IS8232A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0411455A (pt) | 2006-07-18 |
| AR044802A1 (es) | 2005-10-05 |
| AU2004247611A1 (en) | 2004-12-23 |
| CA2527608A1 (en) | 2004-12-23 |
| IS8232A (is) | 2006-01-13 |
| US20060194879A1 (en) | 2006-08-31 |
| CN1805922A (zh) | 2006-07-19 |
| GB0314136D0 (en) | 2003-07-23 |
| JP2006527767A (ja) | 2006-12-07 |
| KR20060017646A (ko) | 2006-02-24 |
| UY28371A1 (es) | 2005-01-31 |
| CO5650229A2 (es) | 2006-06-30 |
| IL172168A0 (en) | 2009-02-11 |
| MXPA05013713A (es) | 2006-06-27 |
| JP3836498B1 (ja) | 2006-10-25 |
| WO2004110985A1 (en) | 2004-12-23 |
| ZA200510199B (en) | 2006-12-27 |
| SA04250170B1 (ar) | 2007-10-29 |
| NO20055923L (no) | 2006-01-06 |
| TW200503678A (en) | 2005-02-01 |
| EP1638921A1 (en) | 2006-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2448665C (en) | Sustained-release analgesic compounds | |
| RU2005138369A (ru) | Фармацевтически полезные соли производных карбоновой кислоты | |
| JP2011527334A5 (ru) | ||
| JPH11512438A (ja) | 末梢性活性抗痛覚過敏オピエート | |
| RU2005135016A (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| ZA200408990B (en) | Combination of a DPP IV inhibitor and a cardiovascular compound | |
| JP2006501295A5 (ru) | ||
| RU2008106058A (ru) | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона | |
| CA2621404A1 (en) | Novel heterobicyclic derivatives | |
| RU2005123802A (ru) | Производные адамантана, способы их получения и содержащие их фармацевтические композиции | |
| EA200601287A1 (ru) | Производные (3-оксо-3,4-дигидрохиноксалин-2-иламино) бензамида и родственные соединения в качестве ингибиторов гликогенфосфорилазы для лечения диабета и ожирения | |
| JPH08505133A (ja) | 解熱方法および鎮痛方法並びに光学的に純粋なｒ−ケトロラックを含む組成物 | |
| US20150080473A1 (en) | N-Substituted Benzenepropanamide or Benzenepropenamide Derivatives for use in the Treatment of Pain and Inflammation | |
| JP2009514912A5 (ru) | ||
| RU2019128534A (ru) | Химические соединения для лечения туберкулеза | |
| RU2004131822A (ru) | Амиды пиперазинил- или пиперидиниламинсульфаминовой кислоты в качестве ингибиторов стероидной сульфатазы | |
| EP2475361A1 (en) | N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation | |
| RU2005141061A (ru) | Аминные соли (-)-2-{(4-гидроксифенил)этил)тио}-3-{4-2-{4-{(метилсульфаонил)окси}фенокси}этил)фенил}пропановой кислоты и их применение в медицине | |
| CA2964684A1 (en) | Composition for the treatment of conditions involving muscular pain | |
| CN111094259B (zh) | 止痛化合物 | |
| RU2007126748A (ru) | Трис(гидроксиметил) метиламинная соль или этаноламинная соль (2)-2-этокси-3-(2-[гексил(2-фенилэтил)амино]-2-оксоэтокси)фенил)пропановой кислоты | |
| KR930702332A (ko) | Cck 길항제용 프로드러그 | |
| DE60300683D1 (de) | Prucaloprid-n-oxid | |
| JP5985985B2 (ja) | 胃腸への影響が減少した即効型ナプロキセン組成物 | |
| RU2002120366A (ru) | Новые производные имидазолия и фармацевтические композиции на их основе |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080910 |